Novartis’s Xolair (omalizumab) Prefilled Syringe for Self-Injection Receives the US FDA’s Approval Across All Indications

April 13, 2021 Auto Bot approval, FDA, Moderate, Nasal Polyps, Novartis, receives, regulatory, Severe 0

Shots:

  • The US FDA has approved the sBLA for a new self-administration option for Xolair in patients across all approved indications in the US
  • The use of the therapy across multiple indications is based on the efficacy and safety profile of Xolair in allergic asthma, CIU, and nasal polyps, supported with a clinical development program, which includes 10 P- III studies
  • Xolair is the only FDA-approved biologic designed to target and block IgE. Genentech and Novartis work together to develop and co-promote Xolair in the US

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Bare Sky Marketing

The post Novartis’s Xolair (omalizumab) Prefilled Syringe for Self-Injection Receives the US FDA’s Approval Across All Indications first appeared on PharmaShots.